352 related articles for article (PubMed ID: 25278514)
1. Does imaging αvβ3 integrin expression with PET detect changes in angiogenesis during bevacizumab therapy?
Rylova SN; Barnucz E; Fani M; Braun F; Werner M; Lassmann S; Maecke HR; Weber WA
J Nucl Med; 2014 Nov; 55(11):1878-84. PubMed ID: 25278514
[TBL] [Abstract][Full Text] [Related]
2. Imaging of α
Grönman M; Tarkia M; Kiviniemi T; Halonen P; Kuivanen A; Savunen T; Tolvanen T; Teuho J; Käkelä M; Metsälä O; Pietilä M; Saukko P; Ylä-Herttuala S; Knuuti J; Roivainen A; Saraste A
J Transl Med; 2017 Jun; 15(1):144. PubMed ID: 28629432
[TBL] [Abstract][Full Text] [Related]
3. Can 111In-RGD2 monitor response to therapy in head and neck tumor xenografts?
Terry SY; Abiraj K; Lok J; Gerrits D; Franssen GM; Oyen WJ; Boerman OC
J Nucl Med; 2014 Nov; 55(11):1849-55. PubMed ID: 25349221
[TBL] [Abstract][Full Text] [Related]
4. Imaging integrin αvβ3 on blood vessels with 111In-RGD2 in head and neck tumor xenografts.
Terry SY; Abiraj K; Frielink C; van Dijk LK; Bussink J; Oyen WJ; Boerman OC
J Nucl Med; 2014 Feb; 55(2):281-6. PubMed ID: 24408894
[TBL] [Abstract][Full Text] [Related]
5. Novel (64)Cu- and (68)Ga-labeled RGD conjugates show improved PET imaging of α(ν)β(3) integrin expression and facile radiosynthesis.
Dumont RA; Deininger F; Haubner R; Maecke HR; Weber WA; Fani M
J Nucl Med; 2011 Aug; 52(8):1276-84. PubMed ID: 21764795
[TBL] [Abstract][Full Text] [Related]
6. In Vivo Characterization of 4
Lobeek D; Franssen GM; Ma MT; Wester HJ; Decristoforo C; Oyen WJG; Boerman OC; Terry SYA; Rijpkema M
J Nucl Med; 2018 Aug; 59(8):1296-1301. PubMed ID: 29626124
[TBL] [Abstract][Full Text] [Related]
7. Comparison of two new angiogenesis PET tracers 68Ga-NODAGA-E[c(RGDyK)]2 and (64)Cu-NODAGA-E[c(RGDyK)]2; in vivo imaging studies in human xenograft tumors.
Oxboel J; Brandt-Larsen M; Schjoeth-Eskesen C; Myschetzky R; El-Ali HH; Madsen J; Kjaer A
Nucl Med Biol; 2014 Mar; 41(3):259-67. PubMed ID: 24417983
[TBL] [Abstract][Full Text] [Related]
8. [
Lang CI; Döring P; Gäbel R; Vasudevan P; Lemcke H; Müller P; Stenzel J; Lindner T; Joksch M; Kurth J; Bergner C; Wester HJ; Ince H; Steinhoff G; Vollmar B; David R; Krause BJ
Cells; 2020 May; 9(6):. PubMed ID: 32486211
[TBL] [Abstract][Full Text] [Related]
9. First-In-Human Study Demonstrating Tumor-Angiogenesis by PET/CT Imaging with (68)Ga-NODAGA-THERANOST, a High-Affinity Peptidomimetic for αvβ3 Integrin Receptor Targeting.
Baum RP; Kulkarni HR; Müller D; Satz S; Danthi N; Kim YS; Brechbiel MW
Cancer Biother Radiopharm; 2015 May; 30(4):152-9. PubMed ID: 25945808
[TBL] [Abstract][Full Text] [Related]
10. Preparation and preclinical evaluation of (66)Ga-DOTA-E(c(RGDfK))2 as a potential theranostic radiopharmaceutical.
Lopez-Rodriguez V; Gaspar-Carcamo RE; Pedraza-Lopez M; Rojas-Calderon EL; Arteaga de Murphy C; Ferro-Flores G; Avila-Rodriguez MA
Nucl Med Biol; 2015 Feb; 42(2):109-14. PubMed ID: 25316595
[TBL] [Abstract][Full Text] [Related]
11. Comparison of Ga-68-Labeled Fusarinine C-Based Multivalent RGD Conjugates and [(68)Ga]NODAGA-RGD-In Vivo Imaging Studies in Human Xenograft Tumors.
Zhai C; Franssen GM; Petrik M; Laverman P; Summer D; Rangger C; Haubner R; Haas H; Decristoforo C
Mol Imaging Biol; 2016 Oct; 18(5):758-67. PubMed ID: 26905697
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of an Integrin α
Gai Y; Jiang Y; Long Y; Sun L; Liu Q; Qin C; Zhang Y; Zeng D; Lan X
Mol Pharm; 2020 Jan; 17(1):349-358. PubMed ID: 31829615
[TBL] [Abstract][Full Text] [Related]
13. [
Provost C; Rozenblum-Beddok L; Nataf V; Merabtene F; Prignon A; Talbot JN
Mol Imaging Biol; 2019 Apr; 21(2):297-305. PubMed ID: 29948641
[TBL] [Abstract][Full Text] [Related]
14. Tumor uptake of the RGD dimeric probe (99m)Tc-G3-2P4-RGD2 is correlated with integrin αvβ3 expressed on both tumor cells and neovasculature.
Liu Z; Jia B; Shi J; Jin X; Zhao H; Li F; Liu S; Wang F
Bioconjug Chem; 2010 Mar; 21(3):548-55. PubMed ID: 20184307
[TBL] [Abstract][Full Text] [Related]
15. Prospective Phase II Trial of [
Carlsen EA; Loft M; Loft A; Czyzewska D; Andreassen M; Langer SW; Knigge U; Kjaer A
J Nucl Med; 2023 Feb; 64(2):252-259. PubMed ID: 35981899
[TBL] [Abstract][Full Text] [Related]
16. alpha(v)beta(3) Integrin-targeting radionuclide therapy and imaging with monomeric RGD peptide.
Yoshimoto M; Ogawa K; Washiyama K; Shikano N; Mori H; Amano R; Kawai K
Int J Cancer; 2008 Aug; 123(3):709-15. PubMed ID: 18498129
[TBL] [Abstract][Full Text] [Related]
17. (64)Cu-labeled tetrameric and octameric RGD peptides for small-animal PET of tumor alpha(v)beta(3) integrin expression.
Li ZB; Cai W; Cao Q; Chen K; Wu Z; He L; Chen X
J Nucl Med; 2007 Jul; 48(7):1162-71. PubMed ID: 17574975
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of two novel ⁶⁴Cu-labeled RGD peptide radiotracers for enhanced PET imaging of tumor integrin αvβ₃.
Hernandez R; Czerwinski A; Chakravarty R; Graves SA; Yang Y; England CG; Nickles RJ; Valenzuela F; Cai W
Eur J Nucl Med Mol Imaging; 2015 Nov; 42(12):1859-68. PubMed ID: 26016906
[TBL] [Abstract][Full Text] [Related]
19. [
Krajcovicova S; Daniskova A; Bendova K; Novy Z; Soural M; Petrik M
Int J Mol Sci; 2021 Jul; 22(14):. PubMed ID: 34299008
[TBL] [Abstract][Full Text] [Related]
20. [68Ga]NODAGA-RGD for imaging αvβ3 integrin expression.
Knetsch PA; Petrik M; Griessinger CM; Rangger C; Fani M; Kesenheimer C; von Guggenberg E; Pichler BJ; Virgolini I; Decristoforo C; Haubner R
Eur J Nucl Med Mol Imaging; 2011 Jul; 38(7):1303-12. PubMed ID: 21487838
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
